BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1304835)

  • 1. [Dihydropyrimidine dehydrogenase activity in lymphocytes: predictive factor for 5-fluorouracil clearance].
    Etienne MC; Milano G; Fleming RA; Thyss A; Renée N; Schneider M; Demard F
    Bull Cancer; 1992; 79(12):1159-63. PubMed ID: 1304835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.
    Fleming RA; Milano G; Thyss A; Etienne MC; Renée N; Schneider M; Demard F
    Cancer Res; 1992 May; 52(10):2899-902. PubMed ID: 1581906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver.
    Chazal M; Etienne MC; Renée N; Bourgeon A; Richelme H; Milano G
    Clin Cancer Res; 1996 Mar; 2(3):507-10. PubMed ID: 9816197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Population study of dihydropyrimidine dehydrogenase in cancer patients].
    Etienne MC; Milano G; Renée N; Lagrange JL; Dassonville O; Thyss A; Schneider M; François E; Fleming R; Demard F
    Bull Cancer; 1995 Sep; 82(9):705-10. PubMed ID: 8535028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
    Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
    Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population study of dihydropyrimidine dehydrogenase in cancer patients.
    Etienne MC; Lagrange JL; Dassonville O; Fleming R; Thyss A; Renée N; Schneider M; Demard F; Milano G
    J Clin Oncol; 1994 Nov; 12(11):2248-53. PubMed ID: 7964939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
    Peng RJ; Dong QM; Shi YX; Cao Y; Zhou ZM; Yuan ZY; Li S; Li H; Jiang WQ
    Ai Zheng; 2006 Aug; 25(8):1039-43. PubMed ID: 16965690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
    Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
    Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review).
    Milano G; Etienne MC
    Anticancer Res; 1994; 14(6A):2295-7. PubMed ID: 7825962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
    Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
    Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of two fluorouracil administration regimens for colorectal cancer.
    Matsusaka S; Yamasaki H; Kitayama Y; Okada T; Maeda S
    Oncol Rep; 2003; 10(1):109-13. PubMed ID: 12469154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.
    Fischel JL; Etienne MC; Spector T; Formento P; Renée N; Milano G
    Clin Cancer Res; 1995 Sep; 1(9):991-6. PubMed ID: 9816071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer.
    Terashima M; Irinoda T; Fujiwara H; Nakaya T; Takagane A; Abe K; Yonezawa H; Oyama K; Inaba T; Saito K; Takechi T; Fukushima M
    Anticancer Res; 2002; 22(2A):761-8. PubMed ID: 12014648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-fluorouracil sensitivity and dihydropyrimidine dehydrogenase activity in advanced gastric cancer.
    Inada T; Ogata Y; Kubota T; Tomikawa M; Yamamoto S; Andoh J; Ozawa I; Hishinuma S; Shimizu H; Kotake K
    Anticancer Res; 2000; 20(4):2457-62. PubMed ID: 10953310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
    Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
    Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combined determination of urine uracil levels and plasma 5-FU clearance for a simple order-made treatment with anticancer agents of FU derivative].
    Morimoto S; Mishima H; Tsujinaka T; Kawato N; Shono Y; Tsuji T; Tabuse K; Nakata I; Saito M; Uenaka K
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):89-94. PubMed ID: 12557710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.
    Etienne MC; Chéradame S; Fischel JL; Formento P; Dassonville O; Renée N; Schneider M; Thyss A; Demard F; Milano G
    J Clin Oncol; 1995 Jul; 13(7):1663-70. PubMed ID: 7602356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer.
    Saeki H; Ito S; Futatsugi M; Kimura Y; Ohga T; Sugimachi K
    Anticancer Res; 2002; 22(6B):3789-92. PubMed ID: 12552994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil.
    Etienne MC; Pivot X; Formento JL; Bensadoun RJ; Formento P; Dassonville O; Francoual M; Poissonnet G; Fontana X; Schneider M; Demard F; Milano G
    Br J Cancer; 1999 Apr; 79(11-12):1864-9. PubMed ID: 10206306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.